Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment

BACKGROUND: New medications for Rheumatoid Arthritis (RA) have emerged in the last decades, including Disease Modifying Antirheumatic Drugs (DMARDs) and biologics. However, there is no known cure, since a significant proportion of patients remain or become non-responders to current therapies. The de...

Descripción completa

Detalles Bibliográficos
Autores principales: Ntari, Lydia, Nikolaou, Christoforos, Kranidioti, Ksanthi, Papadopoulou, Dimitra, Christodoulou-Vafeiadou, Eleni, Chouvardas, Panagiotis, Meier, Florian, Geka, Christina, Denis, Maria C., Karagianni, Niki, Kollias, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063445/
https://www.ncbi.nlm.nih.gov/pubmed/33892739
http://dx.doi.org/10.1186/s12967-021-02764-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063445/
https://www.ncbi.nlm.nih.gov/pubmed/33892739
http://dx.doi.org/10.1186/s12967-021-02764-y

Ejemplares similares